A bill for an act relating to prescription drug affordability, including the creation of a prescription drug affordability board.
Senate File 264 would create a new Prescription Drug Affordability Board in Iowa to study drug pricing and identify prescription drugs that may be creating affordability problems for patients, health plans, state and local governments, and other health care stakeholders. The board would be made up of five governor-appointed members with health care or clinical expertise, subject to senate confirmation, and would operate with strict conflict-of-interest rules, public meeting requirements, and a stakeholder council to provide input from manufacturers, providers, suppliers, and consumers.
The bill directs the board to identify certain high-cost brand-name drugs, biologics, biosimilars, and generic drugs for affordability review. If a review finds that a drug is contributing to an affordability challenge, the board must report its findings to the General Assembly and recommend an upper payment limit for the drug. The bill also requires annual reporting on prescription drug price trends and a separate report on the generic drug market, including effects on premiums, cost-sharing, shortages, and Medicaid spending.
If enacted, the bill would add a new chapter to Iowa law governing prescription drug affordability and create a new state board with authority to collect pricing information, conduct affordability reviews, and recommend upper payment limits for certain drugs. It would also establish a stakeholder council, require regular public reporting, and authorize the board to adopt administrative rules. The bill would affect manufacturers, pharmacy benefit managers, health plans, pharmacies, providers, consumers, and state and local government purchasers by increasing scrutiny of drug pricing and potentially leading to future legislative or regulatory action based on the board's findings.
The bill appears to be framed as a consumer- and cost-focused health care measure, with support implied by its bipartisan list of sponsors and its emphasis on transparency, public input, and affordability. No committee transcript or vote record is provided, so there is no direct evidence of debate or opposition in the materials supplied. The overall tone of the bill text is policy-driven and reform-oriented, aimed at addressing high prescription drug costs rather than limiting access to medications.
The main likely points of contention are the board's potential influence over drug pricing, especially the recommendation of upper payment limits, and the extent of state oversight into pharmaceutical pricing and manufacturer data. Manufacturers may object to disclosure requirements, affordability reviews, and the possibility of price caps, while supporters are likely to emphasize patient affordability, transparency, and protection of public and private payers. Conflict-of-interest restrictions and the composition of the stakeholder council also suggest sensitivity to concerns about industry influence and the fairness of the board's decision-making process.